Sequencing Therapies in the Third-Line and Beyond for Patients With HER2+ Metastatic Breast Cancer
March 14th 2024Doctors Laura Spring and Manali Bhave discuss summarize their recommended sequence of systemic therapy options for HER2-positive metastatic breast cancer, from first-line taxane and dual HER2 blockade through later lines with T-DM1, tucatinib, and other regimens.
Read More
Standard of Care Regimens for Second-Line Treatment of HER2+ Metastatic Breast Cancer
March 7th 2024Laura Spring, MD, and Manali Bhave, MD, discuss findings from the DESTINY-Breast03 trial and how these results have led them to adopt T-DM1 as the new standard of care over lapatinib/capecitabine for second-line treatment of HER2-positive metastatic breast cancer after progression on first-line trastuzumab and a taxane.
Read More
Key Clinical Trials in the First-Line Treatment of HER2+ Metastatic Breast Cancer
March 7th 2024Oncologists discuss key learnings from clinical trials investigating the first-line treatment of patients with HER2-positive metastatic breast cancer, and how these findings help inform their clinical practice regarding selection of optimal systemic therapy regimens.
Read More
Current First-Line Systemic Therapy Options for HER2+ Metastatic Breast Cancer
February 29th 2024Experts discuss considerations around first-line treatment selection for HER2-positive metastatic breast cancer, including when to diverge from the standard-of-care treatment, as well as the role of brain MRIs at diagnosis.
Read More
Clinical Scenario: A 57-Year-Old Woman With Metastatic Breast Cancer
February 29th 2024Two oncologists present the clinical scenario of a 57-year-old woman with metastatic HER2-positive breast cancer to discuss their approach for incorporating recent research into clinical decision making around systemic therapy.
Read More
Dr. Bhave on Promising Anti-HER2 Agents in HER2+ Breast Cancer
October 16th 2019Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.
Read More
Dr. Bhave Discusses [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer
August 12th 2019Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.
Read More